In the phase I clinical trial with RA patients, CIGB814 has been shown to reduce the levels of tumor necrosis factor (TNFα) and interleukin -17, and it also induced a significant decrease in auto-antibodies against citrullinated self-proteins [19]. This evidence concerns the gene TNF and rheumatoid arthritis.